

**Washington State Pharmacy and Therapeutics Committee
Drug Utilization Review Board
Date: August 19, 2020
Time: 9 a.m. to 4 p.m.
GoTo Webinar**

9 a.m.	Welcome & Introductions Pharmacy & Therapeutics Committee Convenes (Reviews drug classes for the WA PDL)	Ginni Buccola, Committee Chair
9:05 a.m.	CGRP- update report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Curtis Harrod, DERP
10:05 a.m.	Pharmacy & Therapeutics Committee Adjourns Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Ginni Buccola, Committee Chair
10:05 a.m.	Oncology agents: <ul style="list-style-type: none"> • Androgen Biosynthesis Inhibitors – Oral • Antiandrogens – Oral • Antineoplastics - Misc Combinations – Oral • Braf Kinase Inhibitors – Oral • Cyclin Dependent Kinases (Cdk) Inhibitors – Oral • Fgfr Kinase Inhibitors – Oral • Hedgehog Pathway Inhibitors – Oral • Mek Inhibitors – Oral • Mtor Kinase Inhibitors – Oral • Multikinase Inhibitors – Oral • Poly (Adp-Ribose) Polymerase (Parp) Inhibitors – Oral • Retinoids – Oral • Topoisomerase Inhibitors – Oral • Tropomyosin Receptor Kinase Inhibitors - Oral 	Umang Patel, Magellan
10:45 a.m.	Break	All
10:55 a.m.	Oncology agents continued: <ul style="list-style-type: none"> • Tyrosine Kinase Inhibitors – Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:50 a.m.	Lunch	All
12:20 p.m.	Ophthalmic agents: <ul style="list-style-type: none"> • Glaucoma agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion • Immunomodulators <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
12:30 p.m.	Respiratory agents: Pulmonary Fibrosing Agents <ul style="list-style-type: none"> • Stakeholder input* 	Umang Patel,

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> • Motion 	Magellan
12:40 p.m.	Smoking Deterrents : misc – other <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
12:45 p.m.	Apple Health Policy: Cytokine & CAM Antagonists <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
1:15 p.m.	Apple Health Policy: Hormone Therapy for Gender Dysphoria <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA Luke Dearden, HCA
1:45 p.m.	Break	All
1:55 p.m.	Apple Health Policy: Migraine Agents: CGRP Receptor Antagonists (Acute) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Luke Dearden, HCA
2:15 p.m.	Apple Health Policy: Migraine Agents : Calcitonin Gene-Related Peptide (CGRP) Receptor Agonists <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Luke Dearden, HCA
2:35 p.m.	Apple Health Policy: Antipsychotics- 2nd generation (Vraylar) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
2:55 p.m.	Apple Health Policy: Gout Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
3:15 p.m.	Apple Health Policy: Tyrosine Kinase Inhibitors – Oral Oncology Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
3:35 p.m.	Drug Utilization Review Board Adjourns	Ginni Buccola, Committee Chair

For all Apple Health (Medicaid) questions, please email AppleHealthPharmacyPolicy@hca.wa.gov.

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.